BioXcel Therapeutics, Inc. (BTAI)

NASDAQ

$--

(--)

After-Hours

BioXcel Therapeutics, Inc. (BTAI) Live Price Chart

Last updated: ⁦2026-10-20 23:06:40⁩. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.

Summary

BioXcel Therapeutics, Inc. (BTAI) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at --, with a market capitalization of -- and a P/E ratio of --. Over the past 52 weeks, its price has ranged from -- to --. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	--
Open	--
Day's High	--
Day's Low	--
Previous Close	--
Volume	--
Average Volume	--
P/E Ratio	--
52-Week High	--
52-Week Low	--
Dividend Yield	--
Earnings Date	--

BioXcel Therapeutics, Inc. (BTAI) After-Hours Stock Price

BioXcel Therapeutics, Inc. (BTAI) is trading at $-- in after-hours trading as of --, -- from the regular-session close of $--.

After-hours trading shows how investors are pricing BTAI after the regular session closes. The current after-hours price is -- the regular-session close, indicating -- after-hours sentiment.

BioXcel Therapeutics, Inc. (BTAI) 7-Day Stock Price Change

Over the past seven days, BioXcel Therapeutics, Inc. (BTAI) moved from $0.75 to $0.07, representing a decline of 90.14% ($0.68).

The stock traded between $0.07 and $0.76 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 47.34 million shares, up versus the previous seven-day period, indicating higher trading activity.

What is BioXcel Therapeutics, Inc. (BTAI)?

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics, Inc. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	29
Exchange	NASDAQ
Company Website	https://www.bioxceltherapeutics.com

How to Buy BioXcel Therapeutics, Inc. (BTAI) Stock on MEXC

Eligible investors can buy real shares of BioXcel Therapeutics, Inc. (BTAI) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for BTAI and Place Your Order

Open the RealStocks trading page and search for BTAI. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is BioXcel Therapeutics, Inc. (BTAI) stock price today?

BioXcel Therapeutics, Inc. (BTAI) is currently trading at --, -- from the previous close of --. Intraday prices update in real time during regular trading hours.

2.Is BTAI stock going up or down today?

As of --, BTAI is trading at --, -- from its previous close of --. The stock has traded between -- and -- during today’s regular session. Past price movements do not guarantee future results.

3.What is BTAI pre-market price?

As of --, BTAI is trading at -- in pre-market trading, -- from the previous close of --. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is BTAI after-hours price?

As of --, BTAI is trading at -- in after-hours trading, -- from the regular-session close of --. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.

5.Is BTAI stock trading now?

BTAI trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does BTAI sit relative to its 52-week high and low?

Over the past 52 weeks, BTAI has traded between a low of -- and a high of --. At --, the stock is positioned --% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is BioXcel Therapeutics, Inc. in?

BioXcel Therapeutics, Inc. (BTAI) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is BioXcel Therapeutics, Inc.'s market capitalization and where is it listed?

BioXcel Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of --. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is BTAI valued in terms of P/E ratio and EPS?

BTAI trades at a P/E ratio of --, based on trailing-twelve-month EPS of --. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does BioXcel Therapeutics, Inc. pay a dividend?

BioXcel Therapeutics, Inc. pays an indicated annual cash dividend of -- per share, with a current dividend yield of --% based on the latest share price. Dividend policies are subject to change at the board's discretion.